Improving the diagnosis and management of neuroendocrine tumors: Utilizing new advances in biomarker and molecular imaging science

Neuroendocrinology

Volumn 98, Issue 1, 2013, Pages 16-30

  Giandomenico, Valeria ^a   Modlin, Irvin M ^b   Pontén, Fredrik ^c   Nilsson, Mats ^d   Landegren, Ulf ^d   Bergqvist, Jonas ^e   Khan, Mohid S ^f   Millar, Robert P ^g   Långström, Bengt ^h   Borlak, Jürgen ⁱ   Eriksson, Barbro ^a   Nielsen, Bengt ^j   Baltzer, Lars ^h   Waterton, John C ^k   Ahlström, Håkan ^l   Öberg, Kjell ^h  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Swedish Human Proteome Resource Project   (United States)

^d UPPSALA UNIVERSITY   (Sweden)

^e UPPSALA UNIVERSITY   (Sweden)

^f UNIVERSITY COLLEGE LONDON   (United Kingdom)

^g MRC Reproductive Biology Unit   (United Kingdom)

^h UPPSALA UNIVERSITY   (Sweden)

ⁱ FRAUNHOFER INSTITUTE FOR TOXICOLOGY AND EXPERIMENTAL MEDICINE   (Germany)

^j BIACORE AB   (Sweden)

^k UNIVERSITY OF MANCHESTER   (United Kingdom)

^l Radiology and Clinical Immunology   (United Kingdom)

more..

Author keywords

Biomarkers; Circulating tumor cells; Molecular imaging; Neuroendocrine tumors

Indexed keywords

BIOLOGICAL MARKER;

ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CELL TRANSFORMATION; CHROMOSOME 18; CIRCULATING TUMOR CELL; GENETIC ANALYSIS; HETEROZYGOSITY LOSS; HIGH THROUGHPUT SCREENING; HUMAN; MASS SPECTROMETRY; MOLECULAR IMAGING; NEUROENDOCRINE TUMOR; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

DISEASE MANAGEMENT; HUMANS; MOLECULAR IMAGING; NEUROENDOCRINE TUMORS; SWEDEN; TUMOR MARKERS, BIOLOGICAL;

EID: 84881558928     PISSN: 00283835     EISSN: 14230194     Source Type: Journal    
DOI: 10.1159/000348832     Document Type: Article

References (73)

1. Vinik AI, Woltering EA, Warner RR, Caplin M, O'Dorisio TM, Wiseman GA, Coppola D, Go VL: NANETS consensus guidelines for the diagnosis of neuroendocrine tumor. Pancreas 2010; 39:713-734.
2. Kloppel G, Couvelard A, Perren A, Kommi-noth P, McNicol AM, Nilsson O, Scarpa A, Scoazec JY, Wiedenmann B, Papotti M, Rindi G, Plockinger U: ENETS Consensus Guidelines for the Standards of Care in Neuroendo-crine Tumors: towards a standardized approach to the diagnosis of gastroenteropan-creatic neuroendocrine tumors and their prognostic stratification. Neuroendocrinolo-gy 2009; 90:162-166.
3. Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, Abdalla EK, Fleming JB, Vauthey JN, Rashid A, Evans DB: One hundred years after 'carcinoid': epidemiology of and prognostic factors for neuroendocrine tumors in 35, 825 cases in the United States. J Clin Oncol 2008; 26:3063-3072.
4. Anthony L, Freda PU: From somatostatin to octreotide LAR: evolution of a somatostatin analogue. Curr Med Res Opin 2009; 25:2989-2999.
5. Rinke A, Muller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, Mayer C, Aminos-sadati B, Pape UF, Blaker M, Harder J, Arnold C, Gress T, Arnold R: Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 2009; 27:4656-4663.
6. Modlin IM, Oberg K, Chung DC, Jensen RT, de Herder WW, Thakker RV, Caplin M, Del-le Fave G, Kaltsas GA, Krenning EP, Moss SF, Nilsson O, Rindi G, Salazar R, Ruszniewski P, Sundin A: Gastroenteropancreatic neuroen-docrine tumours. Lancet Oncol 2008; 9:61-72.
7. Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, Hobday TJ, Okusaka T, Capdevila J, de Vries EG, Tomassetti P, Pavel ME, Hoosen S, Haas T, Lincy J, Lebwohl D, Oberg K: Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011; 364:514-523.
8. Raymond E, Dahan L, Raoul JL, Bang YJ, Bor-bath I, Lombard-Bohas C, Valle J, Metrakos P, Smith D, Vinik A, Chen JS, Horsch D, Hammel P, Wiedenmann B, Van Cutsem E, Patyna S, Lu DR, Blanckmeister C, Chao R, Ruszniewski P: Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011; 364:501-513.
9. Modlin IM, Moss SF, Chung DC, Jensen RT, Snyderwine E: Priorities for improving the management of gastroenteropancreatic neu-roendocrine tumors. J Natl Cancer Inst 2008; 100:1282-1289.
10. Yao JC, Lombard-Bohas C, Baudin E, Kvols LK, Rougier P, Ruszniewski P, Hoosen S, St Peter J, Haas T, Lebwohl D, Van Cutsem E, Kulke MH, Hobday TJ, O'Dorisio TM, Shah MH, Ca-diot G, Luppi G, Posey JA, Wiedenmann B: Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol 2010; 28: 69-76.
11. Pavel ME, Hainsworth JD, Baudin E, Peeters M, Horsch D, Winkler RE, Klimovsky J, Leb-wohl D, Jehl V, Wolin EM, Oberg K, Van Cut-sem E, Yao JC, RADIANT-2 Study Group: Everolimus plus octreotide long-acting re-peatable for the treatment of advanced neuro-endocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet 2011; 378:2005-2012.
12. Yao J, Phan A, Fogelman DR, et al: Randomized run-in study of bevacizumab (B) and everolimus (E) in low-to intermediate-grade neuroendocrine tumors (LGNETs) using perfusion CT as functional biomarker (abstract). J Clin Oncol 2010; 28:4002.
13. Yao JC, Phan A, Hoff PM, Chen HX, Charn-sangavej C, Yeung SC, Hess K, Ng C, Abbruz-zese JL, Ajani JA: Targeting vascular endothe-lial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pe-gylated interferon alpha-2b. J Clin Oncol 2008; 26:1316-1323.
14. Oberg K: Somatostatin-receptor mediated diagnosis and treatment in gastrointestinal neu-roendocrine tumours (GEP-NET's). Rocz Akad Med Bialymst 2005; 50:62-68.
15. Kulke MH, Hornick JL, Frauenhoffer C, Hooshmand S, Ryan DP, Enzinger PC, Mey-erhardt JA, Clark JW, Stuart K, Fuchs CS, Redston MS: O 6-methylguanine DNA meth-yltransferase deficiency and response to te-mozolomide-based therapy in patients with neuroendocrine tumors. Clin Cancer Res 2009; 15:338-345.
16. Kulke MH, Freed E, Chiang DY, Philips J, Zahrieh D, Glickman JN, Shivdasani RA: High-resolution analysis of genetic alterations in small bowel carcinoid tumors reveals areas of recurrent amplification and loss. Genes Chromosomes Cancer 2008; 47:591-603.
17. Jiao Y, Shi C, Edil BH, de Wilde RF, Klimstra DS, Maitra A, Schulick RD, Tang LH, Wolfgang CL, Choti MA, Velculescu VE, Diaz LA Jr, Vogelstein B, Kinzler KW, Hruban RH, Pa-padopoulos N: DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science 2011; 331:1199-1203.
18. Missiaglia E, Dalai I, Barbi S, Beghelli S, Fal-coni M, della Peruta M, Piemonti L, Capurso G, Di Florio A, delle Fave G, Pederzoli P, Croce CM, Scarpa A: Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway. J Clin Oncol 2010; 28:245-255.
19. Biomarkers Definitions Working Group: Bio-markers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001; 69:89-95.
20. Modlin IM, Gustafsson BI, Moss SF, Pavel M, Tsolakis AV, Kidd M: Chromogranin A-biological function and clinical utility in neuro endocrine tumor disease. Ann Surg Oncol 2010; 17:2427-2443.
21. Borbath I, Jamar F, Delaunoit T, Demetter P, Demolin G, Hendlisz A, Pattyn P, Peeters M, Roeyen G, Van Cutsem E, Van Hootegem P, Van Laethem JL, Verslype C, Pauwels S: Diagnostic pitfalls in digestive neuroendocrine tumours. Acta Gastroenterol Belg 2009; 72: 29-33.
22. Modlin IM, Kidd M, Latich I, Zikusoka MN, Eick GN, Mane SM, Camp RL: Genetic differentiation of appendiceal tumor malignancy: a guide for the perplexed. Ann Surg 2006; 244:52-60.
23. Drozdov I, Kidd M, Nadler B, Camp RL, Mane SM, Hauso O, Gustafsson BI, Modlin IM: Predicting neuroendocrine tumor (carci-noid) neoplasia using gene expression profiling and supervised machine learning. Cancer 2009; 115:1638-1650.
24. Grabowski P, Griss S, Arnold CN, Horsch D, Goke R, Arnold R, Heine B, Stein H, Zeitz M, Scherubl H: Nuclear survivin is a powerful novel prognostic marker in gastroenteropan-creatic neuroendocrine tumor disease. Neu-roendocrinology 2005; 81:1-9.
25. Leja J, Essaghir A, Essand M, Wester K, Oberg K, Totterman TH, Lloyd R, Vasmatzis G, De-moulin JB, Giandomenico V: Novel markers for enterochromaffin cells and gastrointestinal neuroendocrine carcinomas. Mod Pathol 2009; 22:261-272.
26. Cunningham JL, Diaz de Stahl T, Sjoblom T, Westin G, Dumanski JP, Janson ET: Common pathogenetic mechanism involving human chromosome 18 in familial and sporadic ileal carcinoid tumors. Genes Chromosomes Cancer 2011; 50:82-94.
27. Giandomenico V: Molecular pathology of gastrointestinal neuroendocrine tumours-selected topics. Diagn Histopathol 2010; 16: 243-250.
28. Nilsson M, Dahl F, Larsson C, Gullberg M, Stenberg J: Analyzing genes using closing and replicating circles. Trends Biotechnol 2006; 24:83-88.
29. Dahl F, Stenberg J, Fredriksson S, Welch K, Zhang M, Nilsson M, Bicknell D, Bodmer WF, Davis RW, Ji H: Multigene amplification and massively parallel sequencing for cancer mutation discovery. Proc Natl Acad Sci USA 2007; 104:9387-9392.
30. Johansson H, Isaksson M, Sorqvist EF, Roos F, Stenberg J, Sjoblom T, Botling J, Micke P, Edlund K, Fredriksson S, Kultima HG, Ericsson O, Nilsson M: Targeted resequencing of candidate genes using selector probes. Nucleic Acids Res 2011; 39:e8.
31. Larsson C, Grundberg I, Soderberg O, Nils-son M: In situ detection and genotyping of individual mRNA molecules. Nat Methods 2010; 7:395-397.
32. Cui T, Hurtig M, Elgue G, Li SC, Veronesi G, Essaghir A, Demoulin JB, Pelosi G, Alimo-hammadi M, Oberg K, Giandomenico V: Paraneoplastic antigen Ma2 autoantibodies as specific blood biomarkers for detection of early recurrence of small intestine neuroen-docrine tumors. PLoS One 2010; 5:e16010.
33. Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, Reuben JM, Doyle GV, Allard WJ, Terstappen LW, Hayes DF: Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004; 351:781-791.
34. Khan MS, Tsigani T, Rashid M, Rabouhans JS, Yu D, Luong TV, Caplin M, Meyer T: Circulating tumor cells and EpCAM expression in neuroendocrine tumors. Clin Cancer Res 2011; 17:337-345.
35. Ponten F, Schwenk JM, Asplund A, Edqvist PH: The Human Protein Atlas as a proteomic resource for biomarker discovery. J Intern Med 2011; 270:428-446.
36. Uhlen M, Ponten F: Antibody-based pro-teomics for human tissue profiling. Mol Cell Proteomics 2005; 4:384-393.
37. Brennan DJ, O'Connor DP, Rexhepaj E, Pon-ten F, Gallagher WM: Antibody-based pro-teomics: fast-tracking molecular diagnostics in oncology. Nat Rev Cancer 2010; 10:605-617.
38. Uhlen M, Oksvold P, Fagerberg L, Lundberg E, Jonasson K, Forsberg M, Zwahlen M, Kampf C, Wester K, Hober S, Wernerus H, Bjorling L, Ponten F: Towards a knowledge-based Human Protein Atlas. Nat Biotechnol 2010; 28:1248-1250.
39. Berglund L, Bjorling E, Oksvold P, Fagerberg L, Asplund A, Szigyarto CA, Persson A, Ot-tosson J, Wernerus H, Nilsson P, Lundberg E, Sivertsson A, Navani S, Wester K, Kampf C, Hober S, Ponten F, Uhlen M: A genecentric Human Protein Atlas for expression profiles based on antibodies. Mol Cell Proteomics 2008; 7:2019-2027.
40. Uhlen M, Bjorling E, Agaton C, Szigyarto CA, Amini B, Andersen E, Andersson AC, Angel-idou P, Asplund A, Asplund C, Berglund L, Bergstrom K, Brumer H, Cerjan D, Ekstrom M, Elobeid A, Eriksson C, Fagerberg L, Falk R, Fall J, Forsberg M, Bjorklund MG, Gumbel K, Halimi A, Hallin I, Hamsten C, Hansson M, Hedhammar M, Hercules G, Kampf C, Larsson K, Lindskog M, Lodewyckx W, Lund J, Lundeberg J, Magnusson K, Malm E, Nils-son P, Odling J, Oksvold P, Olsson I, Oster E, Ottosson J, Paavilainen L, Persson A, Rimini R, Rockberg J, Runeson M, Sivertsson A, Skollermo A, Steen J, Stenvall M, Sterky F, Stromberg S, Sundberg M, Tegel H, Tourle S, Wahlund E, Walden A, Wan J, Wernerus H, Westberg J, Wester K, Wrethagen U, Xu LL, Hober S, Ponten F: A human protein atlas for normal and cancer tissues based on antibody proteomics. Mol Cell Proteomics 2005; 4: 1920-1932.
41. Ponten F, Jirstrom K, Uhlen M: The Human Protein Atlas-a tool for pathology. J Pathol 2008; 216:387-393.
42. Lindskog C, Korsgren O, Ponten F, Eriksson JW, Johansson L, Danielsson A: Novel pancreatic beta cell-specific proteins: antibody-based proteomics for identification of new biomarker candidates. J Proteomics 2012; 75: 2611-2620.
43. Darmanis S, Nong RY, Hammond M, Gu J, Alderborn A, Vanelid J, Siegbahn A, Gustafs-dottir S, Ericsson O, Landegren U, Kamali-Moghaddam M: Sensitive plasma protein analysis by microparticle-based proximity li-gation assays. Mol Cell Proteomics 2010; 9: 327-335.
44. Darmanis S, Nong RY, Vanelid J, Siegbahn A, Ericsson O, Fredriksson S, Backlin C, Gut M, Heath S, Gut IG, Wallentin L, Gustafsson MG, Kamali-Moghaddam M, Landegren U: ProteinSeq: High-performance proteomic analyses by proximity ligation and next generation sequencing. PLoS One 2011; 6:e25583.
45. Soderberg O, Gullberg M, Jarvius M, Ridder-strale K, Leuchowius KJ, Jarvius J, Wester K, Hydbring P, Bahram F, Larsson LG, Lande-gren U: Direct observation of individual endogenous protein complexes in situ by proximity ligation. Nat Methods 2006; 3:995-1000.
46. Clausson CM, Allalou A, Weibrecht I, Mah-moudi S, Farnebo M, Landegren U, Wahlby C, Soderberg O: Increasing the dynamic range of in situ PLA. Nat Methods 2011; 8:892-893.
47. Pu Y, Zhu Z, Liu H, Zhang J, Liu J, Tan W: Using aptamers to visualize and capture cancer cells. Anal Bioanal Chem 2010; 397:3225-3233.
48. Barbas AS, Mi J, Clary BM, White RR: Ap-tamer applications for targeted cancer therapy. Future Oncol 2010; 6:1117-1126.
49. Zhou J, Rossi JJ: Cell-specific aptamer-medi-ated targeted drug delivery. Oligonucleotides 2011; 21:1-10.
50. Berezovski MV, Lechmann M, Musheev MU, Mak TW, Krylov SN: Aptamer-facilitated biomarker discovery (AptaBiD). J Am Chem Soc 2008; 130:9137-9143.
51. Hanrieder J, Wicher G, Bergquist J, Anders-son M, Fex-Svenningsen A: MALDI mass spectrometry based molecular phenotyping of CNS glial cells for prediction in mammalian brain tissue. Anal Bioanal Chem 2011; 401:135-147.
52. Ouyang Z, Cooks RG: Miniature mass spectrometers. Annu Rev Anal Chem (Palo Alto Calif) 2009; 2:187-214.
53. Bergstrom M, Muhr C, Lundberg PO, Berg-strom K, Gee AD, Fasth KJ, Langstrom B: Rapid decrease in amino acid metabolism in prolactin-secreting pituitary adenomas after bromocriptine treatment: a PET study. J Comput Assist Tomogr 1987; 11:815-819.
54. Bergstrom M, Muhr C, Lundberg PO, Lang-strom B: PET as a tool in the clinical evaluation of pituitary adenomas. J Nucl Med 1991; 32:610-615.
55. Yorimitsu H, Murakami Y, Takamatsu H, Nishimura S, Nakamura E: Synthesis and bio-imaging of positron-emitting 15O-labeled 2-deoxy-D-glucose of two-minute half-life. Chem Asian J 2007; 2:57-65.
56. Van der Lely AJ, de Herder WW, Krenning EP, Kwekkeboom DJ: Octreoscan radiorecep-tor imaging. Endocrine 2003; 20:307-311.
57. Velikyan I, Sundin A, Eriksson B, Lundqvist H, Sorensen J, Bergstrom M, Langstrom B: In vivo binding of [68 Ga]-DOTATOC to soma-tostatin receptors in neuroendocrine tumours-impact of peptide mass. Nucl Med Biol 2010; 37:265-275.
58. Orlefors H, Sundin A, Garske U, Juhlin C, Oberg K, Skogseid B, Langstrom B, Berg-strom M, Eriksson B: Whole-body (11)C-5-hydroxytryptophan positron emission tomography as a universal imaging technique for neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and computed tomography. J Clin Endocrinol Metab 2005; 90:3392-3400.
59. Koopmans KP, Neels OC, Kema IP, Elsinga PH, Sluiter WJ, Vanghillewe K, Brouwers AH, Jager PL, de Vries EG: Improved staging of patients with carcinoid and islet cell tumors with 18 F-dihydroxy-phenyl-alanine and 11C-5-hydroxy-tryptophan positron emission tomography. J Clin Oncol 2008; 26:1489-1495.
60. Kauhanen S, Seppanen M, Ovaska J, Minn H, Bergman J, Korsoff P, Salmela P, Saltevo J, Sane T, Valimaki M, Nuutila P: The clinical value of [18F] fluoro-dihydroxyphenylalanine positron emission tomography in primary diagnosis, staging, and restaging of neuroendo-crine tumors. Endocr Relat Cancer 2009; 16: 255-265.
61. Orlefors H, Sundin A, Lu L, Oberg K, Lang-strom B, Eriksson B, Bergstrom M: Carbidopa pretreatment improves image interpretation and visualisation of carcinoid tumours with 11 C-5-hydroxytryptophan positron emission tomography. Eur J Nucl Med Mol Imaging 2006; 33:60-65.
62. Hofmann M, Maecke H, Borner R, Weckesser E, Schoffski P, Oei L, Schumacher J, Henze M, Heppeler A, Meyer J, Knapp H: Biokinetics and imaging with the somatostatin receptor PET radioligand (68)Ga-DOTATOC: preliminary data. Eur J Nucl Med 2001; 28:1751-1757.
63. Kwekkeboom DJ, de Herder WW, van Eijck CH, Kam BL, van Essen M, Teunissen JJ, Krenning EP: Peptide receptor radionuclide therapy in patients with gastroenteropancre-atic neuroendocrine tumors. Semin Nucl Med 2010; 40:78-88.
64. Ruf J, Heuck F, Schiefer J, Denecke T, Elgeti F, Pascher A, Pavel M, Stelter L, Kropf S, Wiedenmann B, Amthauer H: Impact of multiphase (68)Ga-DOTATOC-PET/CT on therapy management in patients with neuroendocrine tumors. Neuroendocrinology 2010; 91: 101-109.
65. Li S, Sun F, Jin ZY, Xue HD, Li ML: Whole-body diffusion-weighted imaging: technical improvement and preliminary results. J Magn Reson Imaging 2007; 26:1139-1144.
66. Takahara T, Imai Y, Yamashita T, Yasuda S, Nasu S, Van Cauteren M: Diffusion weighted whole body imaging with background body signal suppression (DWIBS): technical improvement using free breathing, STIR and high resolution 3D display. Radiat Med 2004; 22:275-282.
67. Poeppel TD, Krause BJ, Heusner TA, Boy C, Bockisch A, Antoch G: PET/CT for the staging and follow-up of patients with malignancies. Eur J Radiol 2009; 70:382-392.
68. Pichler BJ, Judenhofer MS, Pfannenberg C: Multimodal imaging approaches: PET/CT and PET/MRI. Handb Exp Pharmacol 2008; 185:109-132.
69. Gaa J, Rummeny EJ, Seemann MD: Whole-body imaging with PET/MRI. Eur J Med Res 2004; 9:309-312.
70. Liapi E, Geschwind JF, Vossen JA, Buijs M, Georgiades CS, Bluemke DA, Kamel IR: Functional MRI evaluation of tumor response in patients with neuroendocrine hepatic metastasis treated with transcatheter arterial chemoembolization. AJR Am J Roentgenol 2008; 190:67-73.
71. Leach MO, Brindle KM, Evelhoch JL, Griffiths JR, Horsman MR, Jackson A, Jayson GC, Jud-son IR, Knopp MV, Maxwell RJ, McIntyre D, Padhani AR, Price P, Rathbone R, Rustin GJ, Tofts PS, Tozer GM, Vennart W, Waterton JC, Williams SR, Workman P: The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations. Br J Cancer 2005; 92:1599-1610.
72. Mross K, Drevs J, Muller M, Medinger M, Marme D, Hennig J, Morgan B, Lebwohl D, Masson E, Ho YY, Gunther C, Laurent D, Un-ger C: Phase I clinical and pharmacokinetic study of PTK/ZK, a multiple VEGF receptor inhibitor, in patients with liver metastases from solid tumours. Eur J Cancer 2005; 41: 1291-1299.
73. O'Connor JP, Naish JH, Parker GJ, Waterton JC, Watson Y, Jayson GC, Buonaccorsi GA, Cheung S, Buckley DL, McGrath DM, West CM, Davidson SE, Roberts C, Mills SJ, Mitchell CL, Hope L, Ton NC, Jackson A: Preliminary study of oxygen-enhanced longitudinal relaxation in MRI: a potential novel biomark-er of oxygenation changes in solid tumors. Int J Radiat Oncol Biol Phys 2009; 75:1209-1215.